Comparative Pharmacology
Head-to-head clinical analysis: CAMPATH versus LEMTRADA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAMPATH versus LEMTRADA.
CAMPATH vs LEMTRADA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alemtuzumab is a recombinant humanized monoclonal antibody that binds to CD52, a cell surface antigen expressed on B and T lymphocytes, NK cells, monocytes, and macrophages. Binding induces antibody-dependent cell-mediated cytotoxicity and complement-mediated lysis, resulting in prolonged lymphocyte depletion.
Alemtuzumab is a humanized monoclonal antibody that binds to CD52, a protein expressed on the surface of mature lymphocytes (T and B cells) and to a lesser extent on monocytes, macrophages, and NK cells. Binding to CD52 induces antibody-dependent cell-mediated cytolysis and complement-mediated lysis, resulting in prolonged depletion of circulating lymphocytes.
12 mg/day intravenously over 2 hours, administered for 5 consecutive days (total 60 mg). For patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the recommended dose is 3 mg/day intravenously on day 1, 10 mg/day on day 2, and 30 mg/day on day 3 (dose escalation), followed by 30 mg/day three times per week on alternate days for up to 11 weeks (total cumulative dose up to 640 mg).
12 mg/day intravenously over 4 hours on 5 consecutive days (total 60 mg), followed by 12 mg/day intravenously over 4 hours on 3 consecutive days (total 36 mg) 12 months later.
None Documented
None Documented
Terminal half-life approximately 12 days (range 6-21 days) after repeated doses, supporting weekly dosing in CLL.
12.7 days (range 7.7–22.1 days) after multiple doses; clinically relevant for prolonged lymphocyte depletion.
Clearance via opsonization and degradation in reticuloendothelial system; negligible renal or biliary excretion (<1% unchanged).
Renal (primarily via catabolism to peptides and amino acids, minimal intact drug in urine). No specific biliary or fecal elimination data.
Category C
Category C
Monoclonal Antibody, Antineoplastic
Monoclonal Antibody